284 related articles for article (PubMed ID: 23460714)
1. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Argiris A; Ghebremichael M; Gilbert J; Lee JW; Sachidanandam K; Kolesar JM; Burtness B; Forastiere AA
J Clin Oncol; 2013 Apr; 31(11):1405-14. PubMed ID: 23460714
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Argiris A; Buchanan A; Brockstein B; Kolesar J; Ghebremichael M; Pins M; Hahn K; Axelrod R; Forastiere A
Cancer; 2009 Oct; 115(19):4504-13. PubMed ID: 19634157
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
Limaye S; Riley S; Zhao S; O'Neill A; Posner M; Adkins D; Jaffa Z; Clark J; Haddad R
Oral Oncol; 2013 Aug; 49(8):835-41. PubMed ID: 23727257
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Kushwaha VS; Gupta S; Husain N; Khan H; Negi MP; Jamal N; Ghatak A
Cancer Biol Ther; 2015; 16(2):346-51. PubMed ID: 25756517
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
[TBL] [Abstract][Full Text] [Related]
7. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
8. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
[TBL] [Abstract][Full Text] [Related]
9. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A; Bauman JE; Weissman C; Adkins D; Schnadig I; Beauregard P; Bowles DW; Spira A; Levy B; Seetharamu N; Hausman D; Walker L; Rudin CM; Shirai K
Oral Oncol; 2015 Apr; 51(4):383-8. PubMed ID: 25593016
[TBL] [Abstract][Full Text] [Related]
10. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K
J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Burtness BA; Manola J; Axelrod R; Argiris A; Forastiere AA;
Ann Oncol; 2008 May; 19(5):977-83. PubMed ID: 18296423
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
Jiang Y; Yuan Q; Fang Q
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1087-95. PubMed ID: 24728492
[TBL] [Abstract][Full Text] [Related]
13. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
15. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
16. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Ready N; Jänne PA; Bogart J; Dipetrillo T; Garst J; Graziano S; Gu L; Wang X; Green MR; Vokes EE;
J Thorac Oncol; 2010 Sep; 5(9):1382-90. PubMed ID: 20686428
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Price KA; Azzoli CG; Krug LM; Pietanza MC; Rizvi NA; Pao W; Kris MG; Riely GJ; Heelan RT; Arcila ME; Miller VA
J Thorac Oncol; 2010 Oct; 5(10):1623-9. PubMed ID: 20871262
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
Caponigro F; Massa E; Manzione L; Rosati G; Biglietto M; De Lucia L; Sguotti C; Sganga P; Avallone A; Comella P; Mantovani G; Comella G
Ann Oncol; 2001 Feb; 12(2):199-202. PubMed ID: 11300324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]